Stem Cell Clinical Trials - Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and Radiation Therapy with Donor Bone Marrow Transplantation in Treating Patients with Hematologic Cancer RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Tacrolimus and mycophenolate mofetil may prevent this from happening. PURPOSE: This phase II trial is studying how well giving chemotherapy, tacrolimus, mycophenolate mofetil, and radiation therapy together with allogeneic bone marrow transplantation works in treating patients with hematologic cancer. OBJECTIVES: Determine the efficacy of combined immunosuppression before and after nonmyeloablative HLA-haploidentical bone marrow transplantation, in terms of donor engraftment at day 84, in patients with high-risk hematologic malignancies. Determine the safety of this regimen, in terms of incidence and severity of graft-vs-host disease and non-relapse-related mortality at day 200, in these patients. OUTLINE: Conditioning regimen: Patients receive fludarabine IV over 1 hour on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 and -5, and total body irradiation on day -1. Bone marrow infusion: Bone marrow from an HLA-haploidentical donor is infused on day 0. Post-transplant immunosuppression: Patients receive cyclophosphamide IV over 1 hour on day 3. Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus IV over 4 hours or orally (when tolerated) beginning on day 4 and continuing until day 180 in the absence of GVHD. Oral mycophenolate mofetil is administered three times daily on days 4-35. Patients receive filgrastim (G-CSF) IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients are followed annually.
